Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion

Bernd Jahrsdörfer,1 Angelika Vollmer,2 Sue E. Blackwell,3 Julia Maier,2 Kai Sontheimer,1 Thamara Beyer,1 Birgit Mandel,2 Oleg Lunov,1 Kyrillo Tron,4 G. Ulrich Nienhaus,4,5 Thomas Simmet,1 Klaus-Michael Debatin,2 George J. Weiner,3 and Dorit Fabricius2

1Institute of Pharmacology of Natural Products and Clinical Pharmacology and 2Department of Pediatrics, University of Ulm, Ulm, Germany; 3Department of Internal Medicine and Holden Comprehensive Cancer Center, University of Iowa, Iowa City; 4Institute of Biophysics, University of Ulm, Ulm, Germany; and 5Institute of Applied Physics and Center for Functional Nanostructures, University of Karlsruhe (TH), Karlsruhe, Germany

Human plasmacytoid dendritic cells (pDCs) are crucially involved in the modulation of adaptive T-cell responses in the course of neoplastic, viral, and autoimmune disorders. In several of these diseases elevated extracellular levels of the serine protease granzyme B (GrB) are observed. Here we demonstrate that human pDCs can be an abundant source of GrB and that such GrB+ pDCs potently suppress T-cell proliferation in a GrB-dependent, perforin-independent manner, a process reminiscent of regulatory T cells. Moreover, we show that GrB expression is strictly regulated on a transcriptional level involving Janus kinase 1 (JAK1), signal transducer and activator of transcription 3 (STAT3), and STAT5 and that interleukin-3 (IL-3), a cytokine secreted by activated T cells, plays a central role for GrB induction. Moreover, we find that the immunosuppressive cytokine IL-10 enhances, while Toll-like receptor agonists and CD40 ligand strongly inhibit, GrB secretion by pDCs. GrB-secreting pDCs may play a regulatory role for immune evasion of tumors, antiviral immune responses, and autoimmune processes. Our results provide novel information about the complex network of pDC–T-cell interactions and may contribute to an improvement of prophylactic and therapeutic vaccinations. (Blood. 2010;115:1156-1165)

Introduction

Plasmacytoid dendritic cells (pDCs) represent a central link between innate and adaptive immunity and play a crucial role in viral, autoimmune, and neoplastic diseases.1,4 One of their most prominent features is the ability of pDCs to produce and secrete large amounts of type I interferons (IFNs), thereby initiating and orchestrating antiviral immune responses.1,5 pDCs can also function as antigen-presenting cells and stimulate effector T-cell responses.6 However, pDC effects on T-cell subsets can include T-cell anergy (tolerogenic function).7,8 pDCs therefore play an important role in fine-tuning cellular immune responses depending on the microenvironment. Several studies suggest that both the activated T cell–derived cytokine interleukin-3 (IL-3)9 and the immunosuppressive cytokine IL-10 induce a rather tolerogenic pDC phenotype associated with suppression of T-cell responses.10-12 In contrast, activation of pDCs in the presence of ligands for the pDC-characteristic Toll-like receptors (TLRs) TLR7 and TLR91 and for CD4010 results in an immunogenic phenotype with such pDC triggering a proinflammatory immune response including T-cell activation and cytotoxicity.6,13,14

Several inflammatory diseases including viral and autoimmune diseases have been found to be associated with elevated levels of extracellular granzyme B (GrB). Granzymes including GrB have been found to be locally elevated in bronchoalveolar lavage fluid from patients with chronic allergic asthma and in synovial fluid from patients with rheumatoid arthritis.15 Infections with cytomegalovirus after renal transplantation, with the dengue fever virus or with HIV, have been associated with high serum levels of GrB.15 Granzymes such as GrB represent a major constituent of the granules of cytotoxic cells, including cytotoxic T lymphocyte (CTL) and natural killer (NK) cells. The classical function of GrB is induction of apoptosis in target cells recognized by CTLs.16,17 Evidence is growing that apart from its cytotoxic effects, granzymes may also have alternative functions. These include degradation of viral proteins important for assembly and replication,18 cytokine-like effects,19 receptor cleavage,20-22 immunosuppression,15,18,21,24 and matrix degradation and remodeling.25

It is not understood how GrB is secreted into the extracellular space in certain diseases. GrB may escape from the immunologic synapses as cytotoxic lymphocytes degranulate.15 An alternative explanation is the production of GrB from nonclassical sources. This possibility is supported by recent findings that immune cell subsets other than CTL or NK cells are able to produce and secrete active GrB under certain circumstances. These subsets include B cells,26,27 hematopoietic progenitor cells,28 basophils,29 mast cells,30 and IFN-α–activated monocyte-derived DCs.31 Interestingly, GrB expression has also been reported in pDCs,32,33 although its regulation and function in these cells is not clear.

In the present study, we demonstrate that activated human pDCs are an abundant source of GrB protein, and on a cell-by-cell basis, may produce GrB in amounts that exceed GrB produced by classical cytotoxic lymphocytes. In subjects with...
juvenile idiopathic arthritis we find not only significantly elevated levels of GrB in fresh synovial fluid specimens but also high GrB expression in the corresponding synovia-derived pDCs compared with healthy controls. Using pDCs from healthy subjects we investigate in detail how GrB production and secretion in pDCs is regulated by cytokines, TLR ligands, and costimulatory signals. Moreover, we show that pDC-derived GrB is directly delivered to T cells and suppresses T-cell proliferation in a cell contact–dependent and perforin-independent manner, a process reminiscent of regulatory T (Treg) cells.24,36 Our results provide novel insights into how pDCs may regulate antiviral, autoimmune, and antitumor immune responses.

**Methods**

**Human subjects and cell culture**

The present study was approved by the Ethics Committee at the University of Ulm. Peripheral blood from healthy volunteers was acquired after obtaining informed consent from each person in accordance with the Declaration of Helsinki. Alternatively, synovial fluid from pediatric patients with juvenile idiopathic arthritis was acquired during standard therapeutic procedures after obtaining informed consent from patients and parents. Mononuclear cells from peripheral blood (PBMC) or from synovial fluid were immediately isolated and red blood cells were removed according to standard procedures. For pDC isolation the BDCA4+ cell isolation kit II was used according to the manufacturer’s instructions (Milenyi Biotec), resulting in more than 95% cells with a lin-1–BDCA-2+CD123brightMHC class IIhigh phenotype. For in vitro culture, cells were suspended in AIM-V medium (Gibco BRL) supplemented with 10 ng/mL of the human pDC growth factor IL-3 and incubated for 36 hours on 96-well flat-bottom plates (106 cells/mL, 200 μL/well) unless stated otherwise at 37°C and 5% CO2 atmosphere in the presence of various agents as indicated. Purity after 2 days was regularly more than 95% BDCA-2+ cells. For coculture experiments CD4+ T cells or pan-T cells from healthy persons were isolated using the CD4+ T cell isolation kit II or the pan-T cell isolation kit (Miltenyi Biotec) and cultured in AIM-V medium as described.17

**Reagents for functional assays**

Human IL-3 (10 ng/mL) and IL-10 (50 ng/mL) were purchased from PeproTech. The CpG oligodeoxynucleotide (ODN) 2006 (2.5 μg/mL) with the specific sequence 5'-tcg tgc ttg cgt tgt gtc gtr-3' was purchased from Coley Pharmaceutical Group, and imiquimod (5 μg/mL) was purchased from InvivoGen. Phytomethaglutamin (PHA; 10 μg/mL), prostaglandin E2 (PGE2; 10-8 M), cyclohexamide (1 μg/mL), and Z-FAM-FMK (50μM) were purchased from Sigma-Aldrich. Anti-CD3/CD28 antibody-coated beads (0.25 μL per 200 μL per well) were purchased from Dynal Biotech – Invitrogen. Brefedlin A (1 μg/mL) was purchased from Epicentre Technologies. Vasoactive intestinal peptide (VIP; 10-6 M), pyridone 6 (P6; 1 M), Ly294002 (1M), AKT inhibitor VIII (0.5 μM), bafilomycin A (10 nM), and lactacystin (0.1 μM) were purchased from Calbiochem. CD40 ligand (1 μg/mL) and recombinant human active GrB were purchased from Axzora Deutschland. For GrB inhibition experiments, carrier- and preservative-free rabbit anti-human GrB polyclonal antibody (immunoglobulin G [IgG]) from USBiological was used at the concentrations indicated. ImmunoPure rabbit IgG from Pierce served as control IgG.

**Flow cytometry**

For fluorescence-activated cell sorter (FACS) analysis, cells were harvested at the indicated time points and stained as described previously.37 Fluorescein isothiocyanate (FITC)–, phycoerythrin (PE)–, PE-Cy5–, peridinin chlorophyll protein–Cy5.5, PE-Cy7–, or allophycocyanin–labeled antibodies to lin-1, CD3, CD4, CD8, CD123, and MHC II were purchased from BD Biosciences; PE- or allophycocyanin–labeled antibodies to BDCA-2 (CD303) were purchased from Miltenyi Biotec. PE-labeled anti-perforin antibodies were purchased from eBioscience, and PE- or allophycocyanin–labeled anti-GrB antibodies (clone GB12) as well as the corresponding isotype controls were purchased from Invitrogen. For flow cytometric intracellular GrB or perforin detection, cells were incubated at 105 cells/mL for 16 hours, brefedlin A (Epicentre Technologies) was added to a final concentration of 1 μg/mL, and cells were cultured for 4 hours. Intracellular staining was performed using fixation and permeabilization buffers from An Der Grub Bio Research. Briefly, cells were washed and resuspended in fixation buffer, incubated for 15 minutes at room temperature, and washed with PBS. Cells were then resuspended in permeabilization buffer, and FcR blocking reagent (Miltenyi Biotec) was added. After 10 minutes incubation, anti-GrB, anti-perforin, or isotype control monoclonal antibody was added. After another 15 minutes of incubation at room temperature, cells were washed with PBS. Flow cytometric analyses were performed on a FACScalibur or an LSRII (BD Immunocytometry Systems) and data analyzed using FlowJo software (Version 8.7.1, TreeStar).

**GrB ELISA**

pDCs from healthy persons were magnetically purified to more than 95% purity as outlined above and incubated for 16 hours with either no treatment or in the presence of human IL-3 (10 ng/mL) with or without IL-10 (50 ng/mL). After incubation, supernatants were collected and GrB concentrations determined using a human GrB ELISA kit according to the manufacturer’s instructions (Mabtech). Alternatively, GrB concentrations were detected in serum from healthy subjects or in synovial fluid from patients with juvenile idiopathic arthritis. Briefly, plates (MaxiSorp Nunc-ImmuNo Module; Thermo Fisher Scientific) were coated with the GrB coating antibody (clone GB10; 2 μg/mL) and incubated overnight at 4°C. Nonspecific reactions were blocked with blocking buffer (PBS, 0.5% Tween 20 and 1% bovine serum albumin) for 1 hour at 24°C. Supernatants, serum, synovial fluid (100 μL volume), or standards were placed on 96-well precoated enzyme-linked immunosorbent assay (ELISA) plates and incubated for 2 hours at 24°C. After washing, plates were incubated with equal volumes of the detection antibody (clone GB11-biotin, 1 μg/mL) for 1 hour at 24°C. Plates were then washed and incubated for 1 hour with streptavidin–horseradish peroxidase at 24°C. After addition of the substrate (R&D Systems) plates were analyzed in a Dynatech MR 7000 ELISA reader. The lower limit of GrB detection was 13 pg/mL.

**GrB activity assay**

For demonstration of enzymatic activity of secreted GrB in the supernatants of stimulated pDCs we used a highly specific GrB activity assay according to the manufacturer’s specifications (SensiZyme; Sigma-Aldrich). Briefly, GrB from supernatants and GrB standards derived from active human recombinant GrB (Alexis) were captured on a 96-well plate precoated with anti-GrB antibody. After washing, substrate A (a procenzyme containing the GrB cleavage site) was added to the substrate B (a chromogenic substrate for the active GrB) and the accumulating chromogenic product was detected in a Dynatech MR 7000 ELISA reader at 405 nm after incubation overnight at 37°C.

**GrB ELISPOT**

Human GrB ELISPOT kits were purchased from Cell Sciences, and polyvinylidene difluoride–bottom 96-well plates were from Millipore. The enzyme-linked immunosorbent (ELISPOT) was performed following the manufacturer’s instruction. Briefly, plates were prepared by adding the capture antibody and by blocking with 2% skim milk in PBS. Cells were plated in AIM-V medium at 105/100 μL/well (unless stated otherwise) in the presence of various agents as indicated and cultured for 16 hours. After culture, the detection antibody was added and plates were incubated for 1.5 hours. Streptavidin–alkaline phosphatase was distributed, and plates
were incubated for 1 hour. Finally, 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium buffer was added and color was allowed to develop for 10 minutes at room temperature, followed by rinsing with distilled water. Plates were dried completely, and spots were read on an Immunospot series 1 analyzer using Immunospot 3 software, both from CTL Cellular Technology.

**GrB and perforin RT-PCR**

pDCs from healthy persons were magnetically isolated to a purity of more than 98% and incubated for 16 hours with either no treatment or in the presence of human IL-3 (10 ng/mL) and IL-10 (50 ng/mL). After incubation, the pDC were counted and mRNA from 6 × 10^3 to 9 × 10^5 cells per sample was prepared using a Dynabeads mRNA Direct kit (Invitrogen). Total RNA was reverse-transcribed using Moloney murine leukemia virus reverse transcriptase (Invitrogen) in a 16-µL reaction volume. For the polymerase chain reaction (PCR), 5 µL of the generated cDNA was used per 25 µL of reaction with recombinant Taq DNA polymerase (0.02 U/µL; Invitrogen). Primers used for GrB were as follows: forward primer 5′-CCATCTCAGAAGCTCTAATCTAAT-3′, reverse primer 5′-CCGGGAGGGCTGG-3′ (biomers.net). Primers used for perforin were as follows: forward primer 5′-TGGAGTGGCGCCTCTCAAGTT-3′, reverse primer 5′-GTGCGGTCCCGTATGTGGGAGAT-3′. RPL-32 were used as a housekeeping gene to obtain comparable results. Primers used for reverse primer 5′/H11032.

**Western immunoblot**

pDCs from healthy subjects were purified and incubated for the times indicated at 10^5 cells/500 µL/well with IL-3 (10 ng/mL) with or without IL-10 (50 ng/mL). Cell lysates were prepared and Western immunoblotting was performed according to standard procedures. After washing and blocking, primary antibodies were added, followed by a washing step and incubation with the secondary antibody conjugated to horseradish peroxidase for 1 hour. Finally, membranes were developed, dried, and exposed to a film. Primary antibodies against GrB, pJAK1, pSTAT1, pSTAT3, pSTAT5, and actin were purchased from Cell Signaling Technology, and the antibody against pJAK3 was purchased from Santa Cruz Biotechnology. Secondary antibodies were anti–goat IgG from Sigma-Aldrich Labchemikalien, and anti–rabbit IgG and anti–mouse IgG were from GE Healthcare.

**Fluorescence microscopy**

Purified pDCs from healthy persons were cultured overnight on 96-well plates at 2 × 10^5 cells/200 µL per well in the presence of IL-3 (10 ng/mL) and IL-10 (50 ng/mL). Brefeldin A was added to a final concentration of 1 µg/mL, and cells were cultured for 4 hours. Subsequently, 1.2 × 10^5 cells were pooled and transferred into a FACS tube (BD Biosciences). Cells were then stained on their surface with FITC-labeled antibodies to BDCA-2 (Miltenyi Biotec) and intracellularly with PE-labeled antibodies to GrB or iso-type control (both from Invitrogen) as described above for flow cytometry, but with prolonged incubation for 1 hour. After 2 washing steps, cells were transferred onto 8-well Lab-Tek II chamber slides (USA Scientific), settled for 10 minutes, and cover slips were attached with Vectashield mounting medium (Vector Laboratories) and examined using an Olympus AX70 fluorescence microscope.

**Spinning disk confocal microscopy**

Purified pDCs were cultured for 16 hours in the presence of IL-3 (10 ng/mL) and IL-10 (50 ng/mL). Brefeldin A was added to a final concentration of 1 µg/mL and cells were cultured for 4 hours. Then, pDCs were harvested, stained in FACS tubes with Cell Mask deep red membrane dye (Invitrogen) at 5 µg/mL for 15 minutes at 37°C and then incubated for 1 hour with 25 µL of GranToxiLux fluorogenic GrB substrate in 75 µL of AIM-V medium at room temperature (OncoImmunin). Alternatively, for total GrB staining, pDCs were fixed, permeabilized, blocked with FcR blocking reagent for 10 minutes (Miltenyi Biotec), and stained with anti-GrB-biotin (Abcam) for 15 minutes at room temperature. After washing, cells were resuspended in 100 µL of permeabilization buffer and stained for 15 minutes with streptavidin–Alexa Fluor 488 (Invitrogen). Finally, cells were resuspended in 200 µL of PBS, placed on 8-well Lab-Tek Permanox chamber slides (Nalge Nunc International) coated with fetal calf serum, and spun at 600 for 10 minutes. The sides of the chambers were removed, coverslips were attached with Vectashield mounting medium (Vector Laboratories), and the edges were sealed using Clarion (Pecon), an image-splitting unit (OptoSplit II; Cairn Research), and an EMCCD camera (DV-887; Andor). ImageJ software (National Institutes of Health) was used for subsequent image processing (2-dimensional parallel spectral deconvolution by generalized Tikhonov [reflective] method and 3-dimensional reconstruction).

**Statistics**

Data are expressed as means plus or minus SEM. To determine statistical differences between the means of 2 data columns, the paired 2-tailed Student t test was used. P values were corrected using the Bonferroni method where applicable.

**Results**

**IL-3–activated pDCs express GrB, an effect strongly enhanced by IL-10, but do not express perforin**

Various inflammatory diseases including autoimmune arthritis have previously been associated with elevated levels of GrB as well as with increased frequencies of pDCs. We were able to confirm these findings in synovial fluid from subjects with idiopathic juvenile arthritis and could also show that GrB was highly expressed by pDCs from such synovial fluid (supplemental Figure 1A-B, available on the Blood website; see the Supplemental Materials link at the top of the online article). Because IL-3 is a primary survival factor for pDCs and has recently been reported to play an important role for collagen-induced arthritis in mice, we continued our experiments with isolated PBMCs from healthy donors, which we cultured in the presence of IL-3 and various additional cytokines. Production of GrB by the resulting pDCs was evaluated. Healthy pDC precursors did not express substantial levels of GrB. In contrast, IL-3–driven activation induced strong up-regulation of GrB protein expression (Figure 1A top panel). Similar responses were found when pDC precursors were purified before culturing in IL-3, suggesting that GrB induction was not a secondary effect resulting from stimulation of different cell populations (Figure 1A bottom panel). GrB production by pDCs was strongly enhanced by IL-10 (Figure 1A-B), revealing the combination of IL-3 and IL-10 as the most potent stimulus for GrB expression by pDCs. Immunofluorescence microscopy showed a scattered distribution pattern of GrB within the pDC cytoplasm (Figure 1C). Higher resolution imaging using spinning disk
confocal microscopy revealed a perinuclear and granular localization of GrB (Figure 1D, supplemental Video 1). GrB protein expression by pDCs was inhibited by the translation inhibitor cycloheximide (Figure 1E), and GrB mRNA could be detected using reverse transcription (RT)–PCR (Figure 1F). This indicated that GrB was freshly produced during pDC activation and was not preformed. In contrast, pDC precursors and pDCs cultured with IL-3 or IL-3 plus IL-10 did not express perforin (supplemental Figure 2A-B).

TLR agonists and CD40 ligand inhibit GrB expression in IL-3–activated pDCs

TLR agonists such as imiquimod and the CpG oligodeoxynucleotide ODN 2006 are recognized by pDCs via TLR7 and TLR9, respectively, and induce an immunogenic phenotype in pDCs.1 In the present study, both ODN 2006 and imiquimod inhibited production of GrB expression by pDCs activated with IL-3 alone and IL-3 plus IL-10 (Figure 2A-B). TLR agonist–mediated inhibition of GrB expression in pDCs was further enhanced by other known modulators of pDC phenotype, including CD40 ligand (CD40L), prostaglandin E2 (PGE2), and vasoactive intestinal peptide (VIP; Figure 2C).

IL-3–activated pDCs secrete large amounts of active GrB

Classical GrB producers such as CTL or NK cells secrete GrB during the granule exocytosis phase after cells have recognized and docked to target cells.16,17 In contrast, pDC secretion of GrB occurred independently of other cells since highly purified pDCs were used for secretion experiments. pDCs activated with IL-3– and IL-10–secreted GrB levels up to 2 logs greater than that secreted by T cells stimulated with PHA (Figure 3A). The fraction of pDCs that produced GrB following IL-3 and IL-10 stimulation was much greater than the fraction of T cells that produced GrB in response to PHA as determined by ELISPOT (Figure 3B). Imiquimod and ODN 2006 inhibited secretion of GrB by mature pDCs (Figure 3C), demonstrating that these agents affect both production and secretion of GrB. Similar results were found with a highly sensitive enzyme-linked GrB activity ELISA demonstrating that pDC-derived GrB was enzymatically active (data not shown). Finally, enzymatic activity was further confirmed by visualization of cleaved GrB-specific substrate in the granules of highly purified pDCs using spinning disk confocal microscopy (supplemental Figure 3, supplemental Video 2).

pDC expression and secretion of GrB depend on JAK activation, endosomal acidification, and active intracellular transport

Induction of GrB in cytotoxic cells is known to depend on activation of the JAK/STAT pathway.39 The JAK inhibitor pyridone 6 (P6) efficiently suppressed GrB expression in pDCs. In contrast, no suppression was found with inhibitors of AKT (AKT inhibitor VIII) and PI3 kinase (Ly294002; Figure 4A-B). Bafilomycin A, which prevents protein acidification and degradation in endosomes,
inhibited GrB expression by pDCs. Inhibition of cathepsin-dependent endosomal processing with the inhibitor Z-FA-FMK or of proteasomal processing with the inhibitor lactacystin had little effect. The secretion of GrB by pDCs was strongly dependent on active transport from the endoplasmic reticulum (ER) to the Golgi apparatus, as shown by complete abrogation of GrB secretion by brefeldin A (Figure 4C). P6 and cycloheximide also inhibited GrB secretion by pDCs, providing further evidence that GrB secretion is dependent on JAK phosphorylation and protein translation (Figure 4C). Taken together, these data suggest that GrB expression and secretion by pDCs require JAK activation, protein translation, endosomal acidification, and active transport from the ER to the Golgi apparatus.

GrB expression by pDCs is associated with phosphorylation of JAK/STAT molecules

Further studies were performed to assess the involvement of other molecules in the JAK and STAT pathways, including Western immunoblots for the phosphorylated forms of JAK1, JAK2, JAK3, STAT1, STAT3, and STAT5. For phospho-JAK (pJAK) detection we used purified pDC precursors and pDCs stimulated with IL-3 with or without IL-10 for 10 minutes, whereas for pSTAT detection pDCs were stimulated for 30 minutes. GrB and β-actin blots from pDCs activated for 16 hours served as controls. IL-3 and IL-10 culture of pDCs resulted in strong up-regulation of GrB, pJAK1, pSTAT3, and pSTAT5, weak up-regulation of pJAK3 and pSTAT1, and no up-regulation of pJAK2 (Figure 5). These studies demonstrate induction of GrB in pDCs involves signaling pathways similar to those seen in NK cells or CTLs.

pDC-derived active GrB is delivered to T cells and inhibits T-cell proliferation

The intensity of GrB secretion by pDCs and its rigorous regulation strongly suggest a physiologic role in the modification of immune responses. Because the primary immune cells interacting with dendritic cells are T cells, we tested whether pDC-derived GrB can be delivered to T cells in its active form. To this end we preincubated pDCs in the presence or absence of IL-3 and IL-10 and then started coincubating them with CD4 T cells in the presence of GrB-specific fluorogenic substrate. Using spinning disk confocal microscopy we demonstrated that 1 hour after the beginning of coincubation T cells started to internalize pDC-derived GrB into their cytoplasm. pDCs were highly mobile, and close interaction between GrB pDCs and T cells appeared to be required for GrB to be transferred to T cells (Figure 6, supplemental Video 3A-C). T cells coincubated with GrB pDC (preincubated in the absence of IL-3 and IL-10) did not develop green

**Figure 3. IL-3–activated pDCs secrete large amounts of GrB.** Purified pDCs were cultured for 16 hours in the absence or presence of IL-3 with or without IL-10. (A) GrB in supernatants was measured by ELISA. Bar graphs illustrate average GrB concentrations from 5 independent experiments (values normalized to 10^4 pDCs per well). (B) GrB secretion was determined by a GrB-specific ELISPOT using purified pDCs treated with IL-3 with or without IL-10 or using T cells treated with PHA (positive control). No spots were observed in samples with 4 x 10^5 pDCs per well in the presence of PHA (not shown). (C) GrB ELISA was performed from supernatants of purified pDCs treated with ODN 2006 or imiquimod. Bar graphs illustrate GrB concentrations normalized to 10^5 pDCs per well (n = 10).
fluorescence (supplemental Video 3D), confirming the notion that GrB was indeed pDC-derived and not T cell-derived.

Further studies were done to determine whether pDC-derived GrB has an impact on the proliferative capacity of T cells. pDCs were activated in the presence of various stimuli for 36 hours, washed, and cocultured with allogeneic CFSE-labeled T cells for 6 days. T-cell proliferation was determined by CFSE dilution. pDCs activated in the presence of IL-3 and TLR7 or TLR9 ligands (GrBlow) induced a strong proliferative T-cell response. In contrast, activation of pDCs with IL-3 alone or IL-3 and IL-10 (GrB/H11001) resulted in much lower T-cell proliferation (Figure 7A). To assess the role of GrB, a GrB-specific antibody was added to the cocultures. The anti-GrB antibody, but not a control antibody, enhanced the ability of IL-3/IL-10–activated GrB-secreting pDCs
to induce proliferation of both CD4+ (Figure 7B top panels) and CD8+ (Figure 7B bottom panels) T cells. In the presence of anti-GrB antibody, T-cell proliferation in response to IL-3/IL-10–treated pDCs reached the same levels achieved with TLR ligand–activated pDCs.

**Discussion**

It is becoming increasingly evident that pDC biology is central to the regulation of a wide range of inflammatory immune responses. The studies presented above add yet another layer to the complexity of this network of interactions. Our studies demonstrate that pDCs can produce large amounts of enzymatically active GrB. GrB secretion by pDCs is not accompanied by perforin secretion but is highly regulated by immunomodulatory cytokines, costimulatory signals, and TLR agonists. In particular, IL-3, a cytokine secreted by eosinophils, mast cells, and activated T cells, and IL-10 strongly induce GrB secretion by pDCs. In contrast, CD40 ligand and TLR7 or TLR9 agonists such as imiquimod or CpG ODN are potent inhibitors of pDC-derived GrB. Importantly, pDC-derived GrB is not preformed or stored, but it is produced de novo upon appropriate stimulation. Its secretion requires activation of JAK1, STAT3, and STAT5 and involves protein translation, endosomal acidification, and an active transport from the ER to the Golgi apparatus.

pDCs are considered pivotal sensors of viral infections, critically involved in the initiation and orchestration of antiviral adaptive immune responses.

**Figure 7.** pDC-derived GrB inhibits allogeneic T-cell proliferation. Purified pDCs were activated for 36 hours in the presence of IL-3, IL-10, and ODN 2006 as indicated. Activated pDCs were washed and coincubated for 6 days with CFSE-stained allogeneic T cells at a pDC:T cell ratio of 1:250. Cells were harvested, stained for CD3, CD4, and CD8, and analyzed by 4-color flow cytometry. (A) Dot plots from one representative experiment and bar graphs from 6 independent experiments illustrate the percentage of CD3+ T cells proliferating in response to allogeneic pDCs or anti-CD3/CD28 antibodies. Error bars indicate SEM. Similar responses were obtained with imiquimod instead of ODN 2006 (data not shown). (B) Bar graphs show average percentages of proliferating CD3+CD4+ and CD3+CD8+ T cells in the presence or absence of IL-3 with or without IL-10–cultured pDCs and anti-GrB or control antibodies (both at 50 μg/mL; n = 4). Error bars indicate SEM.
development of autoreactive T cells. Thus, expansion of peripheral T cells at the site of acute viral infection may not be desirable too early because of the potential for extensive auto-reactivity. pDC-derived GrB may act as inhibitor of such early on-site T-cell expansion. The observation that extracellular GrB levels are particularly high in the acute phase of viral infections is consistent with this hypothesis. As soon as highly specific T cells have been selected in the lymph nodes, they express costimulatory molecules on their surfaces and migrate into the joints of patients suffering from rheumatoid arthritis. For example, pDCs migrate into the joints of patients with juvenile idiopathic arthritis (JIA), where they can detect and respond to viral nucleic acids by pDCs. The cytokines identified in the present study are the main stimulus for the induction of GrB in pDCs, namely IL-3 and IL-10, and can also be detected in the environment of neoplastic diseases. This suggests that GrB-secreting pDCs in such an environment could be involved in suppressing the expansion of tumor-specific T cells. Clearly, further studies are needed to investigate whether the regulatory effects of GrB-secreting pDCs on T cells may play a role in immune evasion of such neoplastic diseases.

Evidence is growing that pDCs regulate the intensity of a large variety of inflammatory immune responses. In particular, the role of pDCs in autoimmunity may be due to both a pDC-based response to viruses pathogenically involved in these diseases as well as a direct TLR-based recognition of autoantigens such as self nucleic acids by pDCs. For example, pDCs migrate into the joints of patients with rheumatoid arthritis, resulting in elevated frequencies of pDCs in the synovia and the synovial fluid of these patients. Similarly, various autoimmune diseases with cutaneous lesions, including lupus erythematosus, dermatomyositis, and psoriasis, have been demonstrated to exhibit enhanced frequencies of pDCs in affected areas. Importantly, all of these inflammatory diseases are characterized by both high pDC frequencies as well as elevated levels of extracellular GrB. The source of extracellular GrB has so far been elusive. Although the involvement of GrB release from cytotoxic cells has been discussed, this does not explain why extracellular GrB is not accompanied by the occurrence of extracellular perforin in such diseases. Further evaluation of the role of GrB in pDCs would benefit from evaluation of this finding in murine models; however, to date we have been unable to induce GrB production by murine pDCs, suggesting apparent species differences between mice and humans. Nevertheless, the data presented in this report demonstrate that human pDCs are a potential source of extracellular GrB in inflammatory conditions such as viral and autoimmune diseases in humans. This view is supported by our finding that pDCs in the synovial fluid of patients with juvenile idiopathic arthritis produce high levels of GrB.

Our studies suggest that GrB secretion by pDCs plays a central role in their ability to suppress T-cell proliferation. Evidence for the functional role of GrB is the finding that extracellular inhibition of GrB by specific antibodies completely restored the proliferative response of T cells to allogeneic pDCs. Our findings support the concept that IL-3 alone or in combination with IL-10 turns pDC precursors into tolerogenic pDCs, with GrB representing a key immunosuppressive effector molecule. Because we were able to directly visualize uptake of pDC-derived GrB by T cells, inhibition of T-cell proliferation may be due to either induction of T-cell apoptosis or to cleavage of molecules involved in cellular proliferation such as the ζ-chain of the T-cell receptor. The video microscopy images of pDC–T-cell cocultures and the fact that exogenous addition of active recombinant GrB did suppress T-cell proliferation only at higher concentrations (D.F., unpublished data, March 2009) suggest that close contact between pDCs and T cells is required for a suppressive effect of GrB-secreting pDCs.

On the other hand, our live imaging studies also showed that the involved pDCs were highly mobile and made several contacts before T cells started to develop GrB-dependent fluorescence. This suggests the cellular interactions between GrB-secreting pDCs and T cells are of low avidity and may be quite distinct from the tighter contact between a CTL and a target cell. Moreover, the uptake of pDC-derived GrB into T cells appears to occur independently of perforin, because the latter is not produced by pDCs. Alternative mechanisms of GrB uptake by T cells could include mannose-6-phosphate receptor–mediated or fluid-phase endocytosis. These saturable mechanisms may also explain why the antiproliferative effect of pDC-derived GrB appears to plateau with both IL-3–activated pDCs (that produce less GrB) and IL-3–IL-10–activated pDCs that produce more GrB. Having similar abilities to suppress T-cell proliferation. Although the exact role of perforin for Treg function is still under debate, this does not explain why extracellular GrB is not accompanied by the occurrence of extracellular perforin in such diseases. Further evaluation of the role of GrB in pDCs would benefit from evaluation of this finding in murine models; however, to date we have been unable to induce GrB production by murine pDCs, suggesting apparent species differences between mice and humans. Nevertheless, the data presented in this report demonstrate that human pDCs are a potential source of extracellular GrB in inflammatory conditions such as viral and autoimmune diseases in humans. This view is supported by our finding that pDCs in the synovial fluid of patients with juvenile idiopathic arthritis produce high levels of GrB.

In conclusion, the studies outlined in this report demonstrate that pDCs can secrete large amounts of GrB in response to IL-3 and IL-10. pDC-derived GrB suppresses T-cell proliferation in a perforin-independent manner, similar to what has been described for regulatory T cells. GrB-secreting pDCs may therefore contribute to the suppression of autoreactive T cells such as would be desirable at the site of acute viral infections. Additional studies are needed to assess what role pDC-derived GrB plays in modulating immune responses and how this finding might be used therapeutically. Incomplete activation and expansion of T cells represent a challenge not only in chronic viral infections and for antitumor immune responses, but also for several prophylactic and therapeutic vaccination approaches for viral and neoplastic diseases. Full activation and expansion of T cells may be inhibited by GrB-secreting pDCs, a process that would be beneficial in limiting autoimmunity, but not when induction of a robust antitumor or antiviral immune response is desired. Inhibition of pDC-derived GrB at the time of vaccination may therefore represent a novel strategy to induce more effective and comprehensive immune responses to vaccination.

Acknowledgments

We thank B. Böhm from the Department of Medicine II for permission to use the ELISPOT reader, and A. Westhoff from the Department of Pediatrics for excellent assistance with fluorescence microscopy (University of Ulm, Ulm, Germany).

This work was supported by the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation), from the Ministry of Science, Research, and the Arts Baden-Württemberg, and from the European Social Fund (ESF) within the Schlieben-Lange-Programm to D.F., as well as from the DFG, from the Deutsche José Carreras Leukämie-Stiftung eV, and from the Deutscher Akademischer Austauschdienst (DAAD; German Academic Exchange Service) to B.J. Further support came from the DFG...
through the Center for Functional Nanostructures (CFN) and SFB 497 to G.U.N. Finally, this work was supported by US Public Health Service Grant P50 CA97274 to G.W.

**Authorship**


Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Dorit Fabricius, Department of Pediatrics, University of Ulm, Eythstrasse 24, 89075 Ulm, Germany; e-mail: dorit.fabricius@uni-ulm.de; or Bernd Jahrsdörfer, Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany; e-mail: bernd.jahrsdoerfer@uni-ulm.de

---

**References**


Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion